Pharma & Biotech Insights, Interviews & Features
Biotechnology
11 November 2024 11 November 2024
Today's issue
Refine Search
Pharmaceutical
A number of leading patient organizations in Russia have called on the national government to increase procurements of drugs against hepatitis C, according to recent statements by representatives of associations and some local media, reports The Pharma Letter’s local correspondent. 12 October 2021
Pharmaceutical
Carima Andrady, senior regulatory writer at PharmaLex, provides an Expert View on a key consideration when seeking to secure an Orphan Drug designation (ODD) in Europe. 8 October 2021
Pharmaceutical
High-risk MDS, often referred to as preleukemia, is a chronic form of blood cancer with a significant level of unmet medical need. While no new therapies have been approved in over a decade, that may be about to change, with multiple drugmakers making significant progress. 1 October 2021
Pharmaceutical
The Russian government, together with the Federal Antimonopoly Service (FAS), have agreed to raise prices for more than 30 drugs from the list of vital and essential since January of the current year, reports The Pharma Letter’s local correspondent. 1 October 2021
Pharmaceutical
As September, Duchenne Action Month, comes to a close, we take a look at advances in pharmacological treatments for this rare condition. 30 September 2021
Biosimilars
Establishing a strong presence in biosimilars is the next frontier for Indian life sciences companies. With biosimilars expected to generate major traction in global markets over the next decade, growing from $12 billion in 2020 to at least $36 billion by 2025 at a CAGR of 24%, studies indicate India does have the potential to supply $5 billion worth of biosimilars globally in the next decade if it overcomes some challenges, reports The Pharma Letter’s India correspondent. 28 September 2021
Pharmaceutical
The register of patents for drugs that are currently created in Russia by an initiative of the country’s Ministry of Economy will not allow drugmakers to effectively protect their intellectual property (IP), according to recent statements by representatives of foreign pharmaceutical companies operating in the local market, reports The Pharma Letter’s local correspondent. 28 September 2021
Biotechnology
Of all the chief executives of the world’s major biopharmaceutical companies, the one who could be excused for spending the most sleepless nights so far in 2021 is Michel Vounatsos. 27 September 2021
Pharmaceutical
The aim of the US Food and Drug Administration’s Accelerated Approval Program (AAP) is to expedite the development of new therapies that address an unmet need in the treatment of serious diseases.1 However, recent controversies regarding AAP drugs have brought the program under severe scrutiny. We discuss the pros and cons of the program and how they impact its future. 24 September 2021
Pharmaceutical
Uwe Trinks, global practice lead for pharmacovigilance technologies, IQVIA, provides an Expert View on how the pharmaceutical industry can make a success of new working practices. 21 September 2021
Pharmaceutical
In a world reeling from the coronavirus pandemic, the pharmaceutical industry has been leading the global response, not only for its enormous contribution to the management of COVID-19, but also for its tireless commitment to continue developing therapies for different diseases that afflict populations. 21 September 2021
Generics
Accusations of carterlization and monopoly by India's pharma lobby has got the Indian government revisiting its Production-Linked Incentive (PLI) scheme and inviting fresh applications for the manufacture of certain key starting materials. Several active pharma ingredients (APIs) such as valsartan, losartan, levofloxacin, sulfadiazine, ciprofloxacin, and ofloxacin among others, are to be manufactured under the PLI scheme, reports The Pharma Letter’s India correspondent. 15 September 2021
Pharmaceutical
Binnopharm Group, a Russian pharmaceutical producer will invest more than 2.5 billion roubles ($33 million) in the development of new drugs within the next several years, according to the company which was launched in February this year. 14 September 2021
Biotechnology
In the runup to the annual congress of the European Society of Medical Oncology (ESMO), the event looks set to attract more than 19,000 participants from around the world. 10 September 2021
Biotechnology
For many years, politicians, patients and drugmakers alike have warned about the risk posed by growing antimicrobial resistance, spurred on by liberal use of antibiotics in farming, and in general medical practice. 8 September 2021
Pharmaceutical
The total value of public procurement of drugs in Russia in the first half of 2021 exceeded 400 billion roubles ($5.4 billion), which is almost 30% higher than a year earlier, according to a study conducted by one of Russia’s leading analyst agencies in the field of pharmaceutics DSM Group, reports The Pharma Letter’s local correspondent. 7 September 2021
Biotechnology
Kees Melief, chief scientific officer of ISA Pharmaceuticals, provides an Expert View on why therapeutic cancer vaccines will be a success following many years of being out of favor. 3 September 2021
Biotechnology
All signs point to an M&A boom in late 2021 and throughout 2022. In this episode, Lance Minor, principal and national co-leader of the life sciences practice at BDO, provides valuable insight into current and emerging trends in the biotech investing landscape. 1 September 2021
Generics
Russia again faces a shortage of foreign drugs for the treatment of serious diseases, this time for the treatment arthritis, according to recent statements by representatives of local patent associations and some local media, reports The Pharma Letter’s local correspondent. 31 August 2021
Biotechnology
These are billed as being exciting times for cell and gene therapies, but seasoned observers of the pharmaceutical industry would be forgiven for taking that billing with a pinch of salt. 31 August 2021
Biotechnology
This week, we discuss a novel AI-driven approach to drug development, and its potential to transform the treatment of cancer and autoimmune diseases. 14 November 2024
Biotechnology
An Expert View from Cumulus Oncology about its innovative business model, which is all about improving the efficiency of drug R&D. 11 November 2024
Generics
Indian drugmaker Aurobindo Pharma has taken on the might of China in terms of Penicillin G pricing, and is doing so by leveraging a fully integrated production process at its new plant. Anticipating the price erosion of Penicillin G, the company has put up an integrated plant from scratch. 10 November 2024
Pharmaceutical
Life science investors can be divided into two groups: those who bought Novo Nordisk stock before GLP-1s hit the big time, and those who wish they had. 10 November 2024
Generics
Indian markets are abuzz with a singular refrain. Donald Trump's Presidency of the United States is set to open new opportunities for India, especially in the pharmaceutical sector. 8 November 2024
Biotechnology
According to UNICEF's State of the World's Children 2023 report, in Latin America
and the Caribbean, 6.8 million children did not benefit from vaccination during the
time of the pandemic and in the following two years, progress has not been as
expected either. 7 November 2024
Biotechnology
As India's bioeconomy soars to a remarkable valuation of $151 billion, the government's Biotechnology Industry Research Assistance Council (BIRAC) has underscored the critical need for innovation and private sector investment to unlock further growth. 21 October 2024
Pharmaceutical
An Expert View from Nick Petschek, Managing Director EMEA, Kotter International. 18 October 2024
Biotechnology
Where once the state of play in the cell and gene therapy space was mostly limited to hope and hype around what might be to come, this is increasingly being replaced by action, on-market therapies and genuine expectation of reaching patients—provided companies can avoid some of the sector’s notorious pitfalls. 16 October 2024
Biotechnology
Antibody-drug conjugates (ADCs) represent a transformative class of cancer therapy that combine the targeting ability of antibodies with the cell-killing potential of cytotoxic drugs. 15 October 2024
Biotechnology
At last month’s European Academy of Dermatology and Venereology (EADV) congress in Amsterdam, Novartis presented new early and long-term Phase III data for remibrutinib in chronic spontaneous urticaria (CSU). 14 October 2024
Biotechnology
India's new Biotechnology Research Innovation and Entrepreneurship Development (Bio-RIDE) scheme is a significant step towards consolidating and advancing the country's biotechnology initiative. 7 October 2024
Pharmaceutical
F2G’s September $100m funding round provides the company with crucial funds to
renavigate approval of its lead drug, olorofim. The substantial financing also
highlights the paucity of novel antifungal products in the clinic. 3 October 2024
Pharmaceutical
Timing can be crucial in biotech, and any company that can help optimize radiopharmaceuticals to fight cancer is likely to a hot property right now, given the recent popularity of the field among investors and drugmakers. 2 October 2024
Pharmaceutical
As stakeholders in the pharmaceutical industry, we all have a responsibility to ensure life-saving treatments promptly and safely reach patients regardless of where they live. To this end, by integrating early access programs and other less conventional strategies into a company’s business model for drug distribution, patients who are suffering from life-threatening conditions can gain access to needed treatments in regions where there is a lack of drug accessibility, while at the same time offering benefits to pharmaceutical companies. 2 October 2024
Pharmaceutical
The Russian government has finalized the rules for granting preference to domestic drugs in public procurements, which will come into force in 2025. 1 October 2024
Pharmaceutical
A Feature on M&A, licensing and partnerships hotting up in inflammatory diseases as new targets present new opportunities for future growth. 30 September 2024
Pharmaceutical
India is set to complete 50 new greenfield pharma manufacturing plants in the next two years under its Production-linked Incentive (PLI) scheme for pharma and medical devices. 30 September 2024
Generics
The number of clinical trials of new drugs in Russia is steadily declining, which could be mainly related with the overall reduction of investment activities in the local pharmaceutical market, reports The Pharma Letter’s local correspondent. 30 September 2024
Pharmaceutical
Scarcely anything unites lawmakers in America these days, but the ostensible iniquities of Big Pharma could be a rare exception. 22 September 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze